Real-world use of Daklinza-based regimens complements clinical findings across various HCV patient populations
Results of ALLY-3+ trial in genotype 3 HCV patients with cirrhosis to provide new insights into treating this patient population
Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD | BMS Newsroom
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.